Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Despite being the runner-up in the race to a US approval for a biosimilar of Neulasta, analysts are watching to see if little Coherus could …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
